ANI Pharmaceuticals, Inc.

As of June 30, 2026, ANI Pharmaceuticals, Inc. carries a market capitalization of 1.68B, placing it among publicly traded companies globally. Its enterprise value stands at 1.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ANI Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, ANI Pharmaceuticals, Inc. has 22.97M shares outstanding.

As of June 30, 2026, ANI Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 16.00. The price-to-sales ratio is 1.77, and the price-to-book ratio stands at 3.21.

As of June 30, 2026, ANI Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 9.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.30 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. ANI Pharmaceuticals, Inc. trades at an EV/FCF ratio of 11.94, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.88B versus a market cap of 1.68B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ANI Pharmaceuticals, Inc. maintains a current ratio of 2.91, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 102.22, indicating elevated leverage, while an interest coverage ratio of 14.28 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ANI Pharmaceuticals, Inc. posted a return on equity (ROE) of 20.88, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.49 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.64, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.55, useful for judging operating efficiency across full business cycles. The company generates approximately 899,790.01 in revenue per employee across its workforce of 951.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.75 indicates how many times ANI Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ANI Pharmaceuticals, Inc. recorded 30.01M in income tax expense. That works out to an effective tax rate of 24.04, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 124.82M, leaving 94.80M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, ANI Pharmaceuticals, Inc.'s stock has declined approximately 19.14% over the past 52 weeks. The 50-day moving average sits at 64.25, while the 200-day moving average is 67.41.

Over the twelve months ended June 30, 2026, ANI Pharmaceuticals, Inc. generated 856.38M in revenue and converted that into 94.80M in net income, yielding earnings per share of 4.39. EBITDA reached 206.71M, while operating income came in at 114.23M.

As of June 30, 2026, ANI Pharmaceuticals, Inc. holds 328.97M in cash and equivalents against 534.36M in total debt, resulting in a net debt position of 219.07M. Total book value stands at 522.74M, with working capital of 474.22M providing operational flexibility.

ANI Pharmaceuticals, Inc. produced 165.84M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -19.21M in capital expenditures, free cash flow totaled 146.63M - equivalent to 7.08 per share.

Over the twelve months ended June 30, 2026, ANI Pharmaceuticals, Inc. posted a gross margin of 60.40, reflecting its pricing power and cost economics. The operating margin of 13.34 and net profit margin of 11.07 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, ANI Pharmaceuticals, Inc. paid dividends of 0.01 per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.31, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.28, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ANI Pharmaceuticals, Inc. shareholders.

ANI Pharmaceuticals, Inc.'s most recent stock split took place on July 18, 2013 with a 6:1 split ratio.

As of June 30, 2026, ANI Pharmaceuticals, Inc. has an Altman Z-Score of 3.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.